Nautilus Biotechnology, Inc. $NAUT Shares Sold by Bain Capital Life Sciences Investors LLC

Key Points

• Bain Capital Life Sciences Investors LLC has reduced its stake in Nautilus Biotechnology by 39% in the first quarter, now holding approximately 1,072,421 shares worth $923,000.
• Institutional ownership of Nautilus Biotechnology stands at 50.71%, with several investors increasing their stakes, including Bank of America and Barclays, who boosted their holdings by 37.1% and 17.9%, respectively.
• Nautilus Biotechnology's stock recently traded at $0.67, having a 12-month low of $0.66 and a high of $3.09, while posting a quarterly EPS of ($0.12) that exceeded expectations.

Bain Capital Life Sciences Investors LLC trimmed its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 39.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,072,421 shares of the company's stock after selling 686,579 shares during the quarter. Nautilus Biotechnology makes up approximately 0.1% of Bain Capital Life Sciences Investors LLC's investment portfolio, making the stock its 23rd biggest holding. Bain Capital Life Sciences Investors LLC owned about 0.85% of Nautilus Biotechnology worth $923,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in Nautilus Biotechnology in the first quarter worth $31,000. Cubist Systematic Strategies LLC purchased a new position in Nautilus Biotechnology in the fourth quarter worth $34,000. Fayez Sarofim & Co purchased a new position in Nautilus Biotechnology in the first quarter worth $39,000. Squarepoint Ops LLC purchased a new position in Nautilus Biotechnology in the fourth quarter worth $44,000. Finally, Deutsche Bank AG grew its holdings in Nautilus Biotechnology by 145.2% in the first quarter. Deutsche Bank AG now owns 54,839 shares of the company's stock worth $47,000 after purchasing an additional 32,470 shares during the last quarter. 50.71% of the stock is owned by hedge funds and other institutional investors.

Nautilus Biotechnology Price Performance

NASDAQ NAUT traded up $0.02 on Monday, hitting $0.68. The stock had a trading volume of 170,965 shares, compared to its average volume of 213,927. The business's fifty day moving average price is $0.73 and its 200 day moving average price is $0.82. Nautilus Biotechnology, Inc. has a 52-week low of $0.62 and a 52-week high of $3.09. The stock has a market cap of $85.89 million, a price-to-earnings ratio of -1.31 and a beta of 1.42.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. As a group, sell-side analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.